Status:
NOT_YET_RECRUITING
A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis
Lead Sponsor:
VivaVision Biotech, Inc
Conditions:
Non-infectious Anterior Uveitis
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
This is a multicenter, randomized, single-masked, active-controlled, parallel, Phase III pivotal study in China
Eligibility Criteria
Inclusion
- At the time of signing the informed consent form (ICF), the subject must be aged 18 to 70 years (inclusive);
- At screening, the affected eye is diagnosed with non-infectious anterior uveitis (acute or recurrent acute, only unilateral eye affected patients are included);
- At screening, the ACC grade of the affected eye is 2+ or 3+ \[SUN criteria\];
- At screening, the ACF grade of the affected eye is ≥1 \[SUN criteria\];
Exclusion
- At screening, the affected eye has an ACC grade of 4+ or hypopyon
- Diagnosis of intermediate uveitis, posterior uveitis, or panuveitis in either eye at the time of screening
Key Trial Info
Start Date :
October 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2027
Estimated Enrollment :
152 Patients enrolled
Trial Details
Trial ID
NCT07136805
Start Date
October 1 2025
End Date
April 30 2027
Last Update
August 22 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.